PhRMA members can enhance the industry's image by making clinical trial results available to the public, writes former Pfizer Global Research President John LaMattina in an open letter to PhRMA. Also, putting a human face of the life-changing research done by pharmaceutical scientists would help, he writes. "Not many have had the chance to see the good that this industry does," LaMattina writes. "[U]nless these beliefs are changed, people will view our products as overpriced drugs with little potential benefit and with hidden safety issues."
Published in Brief: